SOURCE: BioMedReports

BioMedReports

June 22, 2011 07:01 ET

Trade Catalyst: Upcoming Paper to Spotlight Potential of Virus to Treat Certain Lung Cancer Patients

LOS ANGELES, CA--(Marketwire - Jun 22, 2011) - Researchers from The Ohio State University, Georgetown University, and Oncolytics Biotech (NASDAQ: ONCY), a Calgary-based biotechnology company, will present a paper on their findings about a type of virus known as the human reovirus, which possesses a remarkable trait: It can replicate inside and kill cancer cells that feature a common mutation (known as an "activated Ras pathway"), while leaving the body's normal cells alone.

The new study report will present findings at the upcoming 14th World Conference on Lung Cancer, to be held July 3-7 in Amsterdam, The Netherlands.

It appears Reovirus has the potential to treat certain lung cancer patients when the reovirus is combined with two other substances known as paclitaxel and carboplatin, and that is significant given that lung cancer (both small cell and non-small cell) is the second most common cancer in both men (after prostate cancer) and women (after breast cancer). In fact, it accounts for about 15% of all new cancers.

A special report about what this development could mean for biotech investors is available now at BioMedReports -- home of the Complete Database of Trade Catalysts, Clinical Trials and Upcoming FDA and World-Wide Regulatory Decisions.

Find today's special report on Oncolytics Biotech today at:

http://biomedreports.com/2011062269239/new-study-spotlights-potential-of-virus-to-treat-certain-lung-cancer-patients.html

In addition, investors interested in make more profitable trades and upcoming news catalysts can our trade alerts at:

http://biomedreports.com/access-our-exclusive-fda-and-clinical-trials-calendars.html

News developments and live healthcare sector updates are available constantly via twitter at: http://twitter.com/BioMedReports

About BioMedReports.Com

BioMedReports is a news portal covering the biomedical news and financial sector. BioMedReports is not paid or compensated to report the news and developments of publicly traded companies in the healthcare sector of the markets. Full disclosures and information about these stocks and news are available at BioMedReports.Com

Contact Information

  • Media Contacts Only:
    Mary Davila
    Assistant Editor
    BioMedReports.Com
    e-mail: Email Contact
    Tel: +1 323 472 4480
    Fax: +1 888 210 3556